HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 292/6/E1775    most recent 00624.2006v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Cusi, K. Articles by Cersosimo, E. Search for Related Content PubMed PubMed Citation Articles by Cusi, K. Articles by Cersosimo, E.

Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes

¹Diabetes Division, Department of Medicine; and ²Audie L. Murphy Veterans Administration Medical Center, The University of Texas Health Science Center at San Antonio, San Antonio, Texas

Submitted 17 November 2006 ; accepted in final form 6 February 2007

Elevated plasma FFA cause -cell lipotoxicity and impair insulin secretion in nondiabetic subjects predisposed to type 2 diabetes mellitus [T2DM; i.e., with a strong family history of T2DM (FH+)] but not in nondiabetic subjects without a family history of T2DM. To determine whether lowering plasma FFA with acipimox, an antilipolytic nicotinic acid derivative, may enhance insulin secretion, nine FH+ volunteers were admitted twice and received in random order either acipimox or placebo (double-blind) for 48 h. Plasma glucose/insulin/C-peptide concentrations were measured from 0800 to 2400. On day 3, insulin secretion rates (ISRs) were assessed during a +125 mg/dl hyperglycemic clamp. Acipimox reduced 48-h plasma FFA by 36% (P < 0.001) and increased the plasma C-peptide relative to the plasma glucose concentration or C-peptide/glucose AUC (+177%, P = 0.02), an index of improved -cell function. Acipimox improved insulin sensitivity (M/I) 26.1 ± 5% (P < 0.04). First- (+19 ± 6%, P = 0.1) and second-phase (+31 ± 6%, P = 0.05) ISRs during the hyperglycemic clamp also improved. This was particularly evident when examined relative to the prevailing insulin resistance [1/(M/I)], as both first- and second-phase ISR markedly increased by 29 ± 7 (P < 0.05) and 41 ± 8% (P = 0.02). There was an inverse correlation between fasting FFA and first-phase ISR (r² = 0.31, P < 0.02) and acute (2–4 min) glucose-induced insulin release after acipimox (r² =0.52, P < 0.04). In this proof-of-concept study in FH+ individuals predisposed to T2DM, a 48-h reduction of plasma FFA improves day-long meal and glucose-stimulated insulin secretion. These results provide additional evidence for the important role that plasma FFA play regarding insulin secretion in FH+ subjects predisposed to T2DM.

insulin resistance; lipotoxicity; -cell; family history of T2DM

This article has been cited by other articles:

				C. Brøns, C. B. Jensen, H. Storgaard, N. J. Hiscock, A. White, J. S. Appel, S. Jacobsen, E. Nilsson, C. M. Larsen, A. Astrup, et al. Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men J. Physiol., May 1, 2009; 587(10): 2387 - 2397. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden American College of Endocrinology Pre-Diabetes Consensus Conference: Part Three Diabetes Care, December 1, 2008; 31(12): 2404 - 2409. [Full Text] [PDF]